Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study

Manal S. Fawzy1*, Eman A. Toraih2*, Nagwa M. Aly1, Abeer Fakhr-Eldeen3, Dahlia I. Badran1 and Mohammad H. Hussein4

Abstract

Background: Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Multiple genetic variants in combination with various environmental risk factors have been implicated. This study aimed to investigate the association of twelve thrombotic and atherosclerotic gene variants in combination with other environmental risk factors with CAD risk in a preliminary sample of Egyptian CAD patients.

Methods: Twenty three consecutive CAD patients undergoing diagnostic coronary angiography and 34 unrelated controls, have been enrolled in the study. Genotyping was based on polymerase chain reaction and reverse multiplex hybridization. Five genetic association models were tested. Data distribution and variance homogeneity have been checked by Shapiro-Wilk test and Levene test, respectively; then the appropriate comparison test was applied. Spearman’s rank correlation coefficient was used for correlation analysis and logistic regression has been performed to adjust for significant risk factors. Clustering the study participants according to gene-gene and gene-environment interaction has been done by Detrended Correspondence Analysis (DCA).

Results: The univariate analysis indicated that the five variants; rs1800595 (FVR2; factor 5), rs1801133 (MTHFR; 5,10-methylenetetrahydrofolate reductase), rs5918 (HPA-1; human platelet antigen 1), rs1799752 (ACE; angiotensin-converting enzyme), and rs7412 and rs429358 (ApoE; apolipoprotein E) were significantly associated with CAD susceptibility under different genetic models. Multivariate analysis revealed clustering of the study population into three patient groups (P) and one control group. FVR2 was the most variant associated with CAD patients, combined with the factor V Leiden (FVL) variant in P1 cluster and with both ACE and MTHFR 667C > T in P2. Whereas, P3 was mostly affected by both MTHFR 667C > T and FXIII (factor 13) V89L mutations. When combined with traditional risk factors, P1 was mostly affected by dyslipidemia, smoking and hypertension, while P2 was mostly affected by their fasting blood sugar levels and ApoE variant.

Conclusions: Taken together, these preliminary results could have predictive value to be applied in refining a risk profile for our CAD patients, in order to implement early preventive interventions including specific antithrombotic therapy. Further large scale and follow-up studies are highly recommended to confirm the study findings.

Keywords: Coronary artery disease, Gene variants, Gene-disease interactions, Polymorphism

* Correspondence: manal2_khashana@ymail.com; emantoraih@gmail.com
1Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide [1]. In Egypt it is responsible for 21% of deaths [2] and reported a prevalence of 8.3% [3]. It is one of the complex diseases that are multifactorial or polygenic disorders, caused by multiple genetic variants with low penetrance in combination with various environmental and lifestyle factors [4]. CAD is characterized by long-term atheromatous plaque formation which culminates into atherothrombotic obstructive lesions leading to tissue damage [5]. Atherosclerosis and thrombosis are the two manifestations underlying CAD. It is known that events such as endothelial dysfunction, inflammation, abnormal lipoprotein and homocysteine metabolism, as well as dysfunctional coagulation and fibrinolysis play a key role in the pathogenesis of CAD [6]. In recent years, several genetic variants robustly associated with CAD have been detected by genome-wide association studies (GWAS), mainly in people of European descent [7]. In order to unravel the genetic profile of a sample of the Egyptian CAD patients with respect to these susceptibility loci, twelve variants were analyzed; Additional file 1: Table S1.

Seven polymorphisms associated with thrombotic risk; (i) Factor V (FV): FV Leiden G1691A (R534Q), leads to activated protein C (APC) resistance on the cleavage of factor V and occurs in 20–50% of patients with venous thromboembolism (VTE). It represents one of the most important genetic risk factors for inherited thrombophilia that increases in homozygous state. The contribution of this polymorphism to the pathogenesis of CAD remains controversial [8, 9] (ii) FVR2 haplotype A4070G (H1299R) was found to be in complete linkage disequilibrium with Factor V Leiden and may confer mild APC resistance. When interacting with the Factor V Leiden mutation could produce a more severe APC resistance phenotype and increased the risk for VTE associated with Factor V Leiden by approximately 3-fold [10]. (iii) Prothrombin, (PTH; Factor II) G20210A; the A allele was previously shown to be associated with increased prothrombin levels due to an alteration in the mRNA processing. Its presence with a hypercoagulable state, imply a moderate association with a higher CAD risk [11, 12]. In addition, A allele carriers had about 3-fold elevated risk for cerebral and deep vein thrombosis. This risk increased significantly when combined with FV Leiden [13]. (iv) Factor XIII (FXIII) 163G > T (V34L); most of clinical studies have demonstrated a lower incidence of both venous and arterial thrombosis in carriers of the mutant allele (34Leu) compared to Val/Val carriers [14]. This could be explained by lower plasma level of FXIII in carriers of L34 with increased its activation that result in less stabilized and thinner fibrin clot due to easy dissociation of its 2A and 2B subunits [15] (v) 5,10-Methylenetetrahydrofolate Reductase (MTHFR) C677T and (vi) MTHFR A1298C. The 677TT homozygosity and 677CT/1298 AC compound heterozygote genotypes have been shown to have decreased MTHFR activity and higher predisposition to arterial and venous thrombosis in the presence of additional risk factors [16, 17]. (vii) Plasminogen Activator Inhibitor 1 (PAI-1, Serpin E1) 4G/5G; the 4G allele was previously found to be associated with higher PAI-1 transcription rates and considered to be a mild risk factor for VTE and myocardial infarction (MI) [18].

Other five variants associated with atherosclerosis; (viii) Beta-Fibrinogen (FGB) -455G > A; confers elevated β-fibrinogen plasma levels, which are directly related to the risk of acute coronary syndromes (ACS) [19], premature MI [20] and ischemic stroke [21]. However controversial findings of some researchers that show a protective role of this polymorphism against non-fatal acute MI [22] still present. (ix) Human Platelet Antigen 1 (HPA-1; Gp IIa; integrin b3) L33P (1a/b); studies have shown that, in the normal population, the HPA-1b phenotype results in increased platelet aggregation and fibrinogen binding, thus enhancing the risk of MI [23, 24]. (x) Angiotensin-Converting Enzyme (ACE) 287 bp insertion/deletion (I/D): D allele has been associated with the elevated ACE activity and plasma levels; thereby represents a risk factor for MI in older patients and in smokers [25].xi) Apolipoprotein B (Apo B) R3500Q, that is considered one of the most common single site mutations in the human APOB gene; results in mild to severe hypercholesterolaemia and an increased risk for early onset atherosclerosis [26]. (xii) Apolipoprotein E (Apo E) E2/E3/E4; an important predictor of the plasma lipid profile with E2 shows the lowest and E4 shows the highest LDL (low density lipoprotein) and total cholesterol levels; E4 allele was associated with increased susceptibility to early-onset MI, particularly in smokers [27].

Taken together, this study aimed to assess the presence of previously mentioned mutations and polymorphisms in a sample of Egyptian CAD patients and to correlate the co-existence and combination of these variants with the clinical and laboratory risk factors in attempt to be helpful in refining a risk profile for our CAD patients, in order to determine the need for and the intensity of follow-up or to influence decisions about staged implementation of preventive interventions with behavioral or drug therapy.

Methods
Study participants
The current observational case-control study included consecutive 23 unrelated Egyptian stable CAD patients undergoing diagnostic coronary angiography and 34
controls. Patients were recruited from the Cardiology Department, Suez Canal University (SCU) Hospital, Ismailia, Egypt, during the period between October 2015 and February 2016. Diagnosis of CAD was based on detailed history taking via a structured interview, thorough clinical examination, resting electrocardiography and echocardiography, followed by coronary angiography. Patients with congenital heart disease or non-atherosclerotic coronary artery disease were excluded. Unrelated healthy blood donors were included as controls. They had no past history of cardiovascular problems and had a normal resting ECG. They were included irrespective of concomitant risk factors for CAD such as obesity, family history of CAD, hypertension, diabetes mellitus, etc. Selective coronary angiography was not performed for controls following our institutional ethical guidelines that do not permit to apply invasive procedures for controls in research work. The study was conducted in accordance with the guidelines in the Declaration of Helsinki and approved by the Medical Research Ethics Committee of SCU (approval no. 2734). Written informed consent was obtained from all participants.

Cardiovascular disease (CVD) risk assessment
Cardiovascular risk factors were recorded as described previously [28]. Hypertension was defined if the patient was receiving anti-hypertensive drugs or blood pressure exceeded 140/90 mmHg in repeated measurements. Diabetes was considered as a blood sugar ≥ 200 mg/dl on admission, fasting glycemia ≥ 126 mg/dl in two determinants or prior prescription of hypoglycemic drugs. Dyslipidemia was identified if had at least one of the following: triglycerides (TG) ≥ 150 mg/dl, total cholesterol (TC) > 200 mg/dl, high density lipoprotein (HDL) < 40 mg/dl in males and < 50 mg/dl in females or receiving lipid-lowering drugs. Height and weight were measured in all participants and the body mass index (BMI) was calculated. BMI > 25 and > 30 were considered overweight and obesity, respectively. Individuals who smoked regularly during the previous 12 months were classified as smokers. Other risk factors as lack of exercise and family history of premature CAD (first degree male relatives < 55 years or females < 65 years) were documented [29].

Multiple methods were used for risk assessment: (1) A qualitative individual risk factor approach in which the sum of risk factors was counted using risk factor categories [30]. (2) A quantitative estimate; “Global CAD risk model” using gender-specific coronary disease prediction algorithm which estimates multivariable CAD risk based on the magnitude or degree of the risk factors [31]. The researchers tried to follow the GRIPS (genetic risk prediction studies) guidelines in reporting the current studied data [32], although our study is not a predictive one, but is considered as a preliminary step in risk assessment in our CAD population.

Echocardiography
A two-dimensional conventional echocardiographic study was performed on all patients using the standard views to exclude the presence of structural heart disease using a commercially available system (General Electric Healthcare Company, Vivid seven Dimensions Vingmed and Horten- Norway) with a 2.5-MHz phased array probe. All echocardiographic data [i.e. the systolic (ejection fraction) and diastolic (grade) functions] were interpreted by two independent experts in echocardiography.

Coronary angiography
Selective coronary cineangiography was performed for all patients using standard, modified Seldinger’s technique [33, 34]. Significant obstructive lesions were diagnosed by visual estimation as the presence of ≥ 50% luminal diameter stenosis in at least one major epicardial coronary artery; left main coronary artery (LMCA), left anterior descending (LAD) coronary artery, right coronary artery (RCA), and circumflex coronary artery (Cx) [35]. Basal angiographic characteristics of patients, such as the location and number of diseased vessels were documented [36]. Multivessel disease (MVD) was defined if ≥ 50% luminal narrowing extended to involve two or three major coronary arteries. Vessel scores ranged from 0 to 3, depending on the number of involved vessels.

A modified Gensini score; a quantitative scoring system applied in our hospital protocols, was used to assess CAD extent and severity from coronary angiograms, taking into account the vessel affected and lesion location, the cumulative effect of multiple lesions, the degree of stenosis, and the influence of collaterals [34, 37]. Each item was assigned a number of points. The score for each vessel was calculated separately, and eventually all are added up to give the total score. The following equation was used: severity score x the segment location multiplying factor x collateral adjustment factor [37]. Scores were determined and interpreted by two independent angiographers who were blinded to the clinical data. A Gensini score value greater than 20 was defined as a high Gensini score [38].

Specimen collection and the laboratory investigations
Five milliliter overnight fasting blood samples were collected on both trisodium EDTA (1 mg/ml) tubes for subsequent genetic analysis study and Serum Separator Vacutainer Tubes II (Becton Dickinson Plymouth). After blood clotting, the latter tubes were centrifuged immediately at 2500 rpm for 20 min and the separated serum were aliquoted into eppendorfs (1 ml per aliquot) and stored at -20 °C for subsequent biochemical assay. Fasting blood glucose (FBG), serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and serum triglycerides (TG) were determined by the
enzymatic method using Hitachi 912 automated chemistry analyzer (Roche Diagnostics Co, Mannheim, Germany). Low density lipoprotein-cholesterol (LDL-c) value was calculated by the Friedewald’s equation [39] as all the study serum TG samples were < 400 mg/dl.

**DNA extraction and In vitro amplification**

DNA was isolated from whole blood within 2 h from collection using ABIOpure™ Total DNA (version 2.0) (AllianceBio, Catalog no. M501DP100) following the protocol supplied by the manufacturer. DNA concentration and purity at the absorbance ratio 260/280 nm were determined by NanoDrop ND-1000 spectrophotometer (NanoDrop Tech., Inc. Wilmington, DE, USA). Amplification was performed using biotinylated ready-made primers enclosed in CVD StripAssay kit (ViennaLab Labordiagnostika GmbH, Vienna, Austria) [40]; Fig. 1. Polymerase chain reaction (PCR) was performed in a 25-μl reaction volume containing 15 μl amplification mix, 5 μl of Taq DNA polymerase (0.2 U/μl) in the Taq dilution buffer, and 200 ng DNA template. It was carried out in a T-Professional Basic, Biometra PCR System (Biometra, Gottingen, Germany) at 94 °C for 2 min as pre-PCR, then thermocycling at 94 °C for 15 s, 58 °C for 30 s, and 72 °C for 30 s (35 cycles), with subsequent final extension at 72 °C for 3 min and hold at 4 °C. Amplification products were analyzed by gel electrophoresis (2.5% agarose gel). The following fragment lengths were detected: 134, 165, 173, 202, 223, 254, 283, 324 bp.

**Reverse multiplex hybridization**

Hybridization of amplification products with saline sodium phosphate EDTA (SSPE) buffer containing 0.5% sodium dodecyl sulfate (SDS) for 30 min was performed to the test strips containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. The strip assays cover 12 variants in the following order: FV 1691G > A (Leiden), FV H1299R (R2), Prothrombin

![Fig. 1 Design of CVD strip assay test used in the current study (Ref 4-240). The left strip represents an example of the genotype results of a case in the current study](image)
Sodium azide (NaN₃) was done. Finally, color development was performed using color substrates containing nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in the dark. Genotype interpretation was determined using the enclosed Collector™ sheet with certain scale. Positive and negative control lines were checked for strip validation; Fig. 1. Positively stained lines were visually noted for each polymorphic position by two independent coauthors and signal pattern of bands were translated into schematic results using stripassay® online calculator [41]; (Additional file 2: Figure S1).

Statistical analysis
Data were managed using the “Statistical Package for the Social Sciences (SPSS) for windows” software (version 20.0) with the aid of Deducer for R-2.15.0 and Microsoft excel 2016. Hardy-Weinberg equilibrium in patients and controls was estimated using the Online Encyclopedia for Genetic Epidemiology (OEGE) software [42]. Pairwise linkage disequilibrium (LD) based on the genotyping data was computed using Haplovie software version 4.1. Five genetic association models were used: allelic model, homozygote and heterozygote comparison, dominant and recessive models [43]. Categorical variables were compared using the chi-square (χ²) or Fisher’s exact tests where appropriate, while the Student’s t test was used to compare continuous variables between two groups in case the data distribution was concordant with normal distribution (Shapiro-Wilk test) and after checking variance homogeneity (Levene test). If the data did not meet the criteria mentioned above, the non-parametric Mann Whitney-U (MW) and Kruskal-Wallis tests were applied. Spearman’s rank correlation coefficient was used for correlation analysis. A two-tailed p-value of <0.05 was considered statistically significant. Logistic regression has been performed to adjust for significant risk factors using the backward method. For clustering the study participants according to gene-gene and gene-environment interaction, Detrended Correspondence Analysis (DCA) was implemented in PC-ORD version 5, using the default number of segments 26 and rescaling axes [44].

Results
Baseline characteristics of the study population
The general clinical and biochemical characteristics of the study groups are shown in Table 1. A total of 23 patients (17 men and 6 women) had undergone coronary angiography, while 34 apparently healthy subjects were assigned to the control group. There was no significant difference in the frequency of traditional risk factors of cardiovascular disease between patients and controls (as gender, obesity, family history of CAD, and diabetes mellitus). None of the controls were smokers or hypertensive. However, CAD patients had significantly higher glucose levels and worse lipid profile than controls (p ≤ 0.001). A higher proportion of patients had significantly over three traditional risk factors compared to controls (60.9 and 5.9%, respectively). Coronary angiography revealed that fifth of patients (21.7%) had no occlusion and only 15 out of 23 patients had significant stenosis (≥50% occlusion); 40% (6/15) of whom had complete luminal occlusion. In addition, nearly two-thirds (10/18) of patients with luminal occlusion, had multivessel disease.

Genotype analysis of thrombotic and atherosclerotic variants
The observed genotype distribution of thrombotic and atherosclerotic genes were in agreement with Hardy-Weinberg equilibrium in both patients and controls (p > 0.05). However, genotype frequencies of MTHFR 667C>T in the CAD group and ACE I/D in the control group deviated significantly from the HWE (p = 0.041 and 0.001, respectively), possibly due to low sample size.

Among the studied genes, both coagulation factor II (rs1799963) and ApoB100 (rs5742904) variants were normal in all patients and controls, thus they were excluded from further analyses. As shown in Tables 2 and 3, the univariate model indicated that the 5 SNPs (1) rs1800595 (FVR), (2) rs1801133 (MTHFR), (3) rs5918 (HPA-1), (4) rs1799752 (ACE), and (5) rs7412 and rs429358 (ApoE) were significantly associated with CAD disease under different genetic association models. The heterozygote genotype of FVR 4070A>G was significantly higher in patients than controls (p = 0.024) with OR (95% CI) of 4.8 (1.2 to 18.3) and 3.8 (1.12–13.5) under heterozygote comparison and allelic models, respectively. The mutant homozygote TT genotype of MTHFR 667C>T also showed higher liability of CAD under homozygote comparison and allelic models. Carriers of the HPA-1 b allele were more frequent among patients (0.26) compared to control group (0.12), (p = 0.048). ACE D/D genotype and D allele were more prevalent in CAD patients with OR showing higher susceptibility to develop CAD. Whereas, ApoE E2 variant showed protection against developing CAD (0.32 in controls compared to 0.13 in patients group, p = 0.004), while E3 and E4 individuals were >3 times more liable.
### Table 1: Clinical and biochemical characteristics of CAD patients and controls

| Characteristics          | Controls (n = 34) | Patients (n = 23) | p value | OR (95% CI) |
|--------------------------|-------------------|-------------------|---------|-------------|
| **Age, mean (y)**        | 54.7 ± 10.1       | 54.0 ± 10.1       | 0.810   |             |
| **Gender**               |                   |                   |         |             |
| Females                  | 16 (47.1)         | 6 (26.1)          | 0.166   | Reference   |
| Males                    | 18 (52.9)         | 17 (73.9)         | 2.51 (0.79–7.94) |
| **BMI, kg/m²**           | 27.7 ± 1.86       | 28.1 ± 2.07       | 0.435   |             |
| **Obesity**              | 6 (17.6)          | 5 (21.7)          | 0.742   | 1.29 (0.34–4.88) |
| **Smoking**              | –                 | 13 (56.5)         |         |             |
| **FH CAD**               | 12 (35.3)         | 6 (26.1)          | 0.567   | 0.64 (0.20–2.07) |
| **Hypertension**         | –                 | 10 (43.5)         |         |             |
| **Diabetes**             | 12 (35.3)         | 7 (30.4)          | 0.780   | 0.82 (0.25–2.49) |
| **Dyslipidemia**         | –                 | 19 (82.6)         |         |             |
| **Biochemical data**     |                   |                   |         |             |
| FBS (mg/dl)              | 99.4 ± 25.7       | 145.6 ± 62.2      | <0.001  |             |
| TC (mg/dl)               | 170 ± 18.4        | 207 ± 61.5        | 0.001   |             |
| TG (mg/dl)               | 103 ± 33.1        | 155 ± 54.4        | <0.001  |             |
| LDL-c (mg/dl)            | 74.9 ± 12.6       | 147 ± 66.3        | <0.001  |             |
| HDL-c (mg/dl)            | 48.6 ± 8.3        | 37.8 ± 11.4       | <0.001  |             |
| **No of risk factors**   |                   |                   |         |             |
| ≤3                       | 32 (94.1)         | 9 (39.1)          | <0.001  | Reference   |
| >3                       | 2 (5.9)           | 14 (60.9)         |         | 24.8 (4.75–130) |
| **Premature CAD**        | –                 | 9 (39.1)          |         |             |
| **Previous events**      | –                 | 18 (78.3)         |         |             |
| **Stroke**               | –                 | 1 (4.3)           |         |             |
| **Lesion type**          |                   |                   |         |             |
| 100% Normal              | –                 | 5 (21.7)          |         |             |
| < 50% Occlusion          | –                 | 3 (13.0)          |         |             |
| 50-99% Occlusion         | –                 | 9 (39.2)          |         |             |
| 100% Occlusion           | –                 | 6 (26.1)          |         |             |
| **Lesion site**          |                   |                   |         |             |
| Single VD                | –                 | 8 (34.8)          |         |             |
| Two VD                   | –                 | 4 (17.4)          |         |             |
| Three VD                 | –                 | 6 (26.1)          |         |             |
| **CAD severity**         |                   |                   |         |             |
| Gensini score            | –                 | 14 (1.5–62)       |         |             |
| Vessel score             | –                 | 1.0 (0.0–3.0)     |         |             |
| **Echo findings**        |                   |                   |         |             |
| Ejection fraction        | –                 | 57.4 ± 7.98       |         |             |
| Mild DD                  | –                 | 20 (87.0)         |         |             |
| SWMA                     | –                 | 9 (39.1)          |         |             |

Values are shown as a number (percentage), mean ± standard deviation, or median (quartiles). CAD coronary artery disease; OR (95% CI), Odds ratio (95% confidence interval); FH family history, FBS fasting blood sugar, TC total cholesterol, TG triglycerides, LDL-c low density lipoprotein-cholesterol, HDL-c high density lipoprotein-cholesterol; Risk factors, Age (men ≥ 45 y and women ≥ 55 y), family history of premature coronary artery disease, hypertension, cigarette smoking, diabetes, hypercholesterolemia, low HDL cholesterol <40 mg/dl, hypertriglyceridemia > 200 mg/dl, and obesity; Premature coronary artery disease, <55 years in males and <65 years in females; previous events, previous acute coronary ischemic events; VD vessel disease (defined as luminal narrowing of > 70%); Gensini score to assess disease severity; DD diastolic dysfunction; SWMA, systolic wall motion abnormalities. P value was generated by using Fisher’s exact test, and Student’s t tests. The bold data are statistically significant at p < 0.05.
to have the disease compared to E2 carriers. The adjusted odds ratio for conventional risk factors (gender, age, BMI, family history of heart disease, diabetes, and obesity) further demonstrated that FVR*AG, HPA-1 b/b, and ACE* DD genotypes are independent risk factors for occurrence of CAD.

Among the studied genes, four polymorphisms are located on chromosome 1: FVL (rs6025), FVR (rs1800595), MTHFR (rs1801133), and MTHFR (rs1801131). Haplotype analysis showed the presence of two blocks; block 1 included 667C > T and 1298A > C SNPs of MTHFR gene and block 2 involving F5: Leiden 1691G > A and F5: R2 4070A > G. The marker locations and LD block structure of the haplotype blocks are shown in Fig. 2. Our analysis revealed a significant difference in the distribution of GA haplotype in block 2 between cases and controls (p = 0.039), Table 4.

Interaction of both gene variants and traditional risk factors with disease risk

Genotype frequencies of variants in patients and controls stratified by cardiovascular risk factors are shown in Table 2.
Significant difference of frequencies of SNPs was observed with gender, obesity and diabetes. Multivariate analysis using an ordination method was used for data clustering, Fig. 3. Analysis of the whole gene variants showed a tendency of the studied population to cluster into 4 groups; one control and three patient groups. Among patients’ clusters, FVR was the most effective associated gene variant in most of our CAD patients, combined with the FVL variant in P1 cluster and with both ACE and MTHFR 667C > T in P2 cluster. Whereas, the third patient group (P3) was mostly affected by both MTHFR 667C > T and F13 V89L mutations, Fig. 3a. With the intersection of genes with confounders and traditional risk factors, more discrimination between patients and controls was revealed in Fig. 3b. HDL and family history were the most prominent factors in the control group. Patients were clustered into two groups showing more effect of traditional risk factors than genes; P1 group was mostly affected by dyslipidemia, LDL, total triglyceride, total cholesterol, smoking, and hypertension, with little contributing effect of gene variants (HPA-1, ACE, ApoE, and MTHFR), while P2 cluster was mostly affected by their fasting blood sugar levels and ApoE variant.

Correlation analysis between gene variants and risk factors supported the association between these genes and lipid profile, Additional file 1: Table S4. Four thrombotic and four atherosclerotic gene variants were

| Table 3 | Genotype and allele frequencies of atherosclerotic gene variants in the study population |
|---------|-------------------------------------------------|
| SNP     | Genotypes | Controls (n = 34) | Patients (n = 23) | P values | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---------|-----------|------------------|------------------|----------|------------------|---------------------|
| FGB     | Normal    | 22 (64.7)        | 12 (52.2)        | 0.636    | 1.0              | 1.0                 |
| -455G > A Hetero | 10 (29.4) | 9 (39.1)         | 1.6 (0.5–5.2)    | 0.28 (0.02–3.1) |
| Homo    | 2 (5.9)   | 2 (8.7)          | 1.8 (0.2–14.7)   | 1.65 (0.1–20.2) |
| Dominant model | 12 (35.3) | 11 (47.8)        | 1.6 (0.5–4.9)    |          |
| p HWE   | 0.557     | 0.866            |                  |          |
| MAF (A) | 0.21      | 0.28             | 0.344            |          |
| p         |           |                  |                  |          |
| HPA-1   | a/a       | 26 (76.5)        | 13 (56.5)        | 0.112    | 1.0              | 1.0                 |
| a/b     | 8 (23.5)  | 8 (34.8)         | 2.0 (0.6–6.5)    |          |
| b/b     | 0 (0.0)   | 2 (8.7)          | 9.8 (0.4–21.9)   |          |
| Dominant model | 8 (23.5) | 10 (43.5)        | 2.5 (0.7–7.8)    |          |
| p HWE   | 0.436     | 0.638            |                  |          |
| MAF (b) | 0.12      | 0.26             | 0.048            |          |
| p         |           |                  |                  |          |
| ACE     | I/I       | 6 (17.6)         | 2 (8.7)          | <0.001   | 1.0              | 1.0                 |
| I/D     | 26 (76.5) | 9 (39.1)         | 1.0 (0.1–6.1)    | 2.79 (0.3–29.7) |
| D/D     | 2 (5.9)   | 12 (52.2)        | 18 (2.0–161)     | 88.3 (4.3–179) |
| Dominant model | 28 (82.4) | 21 (91.3)        | 2.3 (0.4–12.2)   |          |
| p HWE   | 0.001     | 0.866            |                  |          |
| MAF (D) | 0.44      | 0.72             | 0.003            | 3.2 (1.4–7.1) |
| p         |           |                  |                  |          |
| ApoB    | Normal    | 34 (100)         | 23 (100)         | NA       | NA               | NA                  |
| R3500Q  | p HWE     | NA               | NA               |          |                  |
| ApoE    | E2/E2     | 0 (0.0)          | 1 (4.3)          | 0.009    | 1.0              |          |
| E2/E3/E4 | E2/E4    | 2 (5.9)          | 1 (4.3)          | 0.2 (0.0–8.8) |
| E2/E3    | 20 (58.8) | 3 (13.0)         | 0.05 (0.0–1.6)   |          |
| E3/E3    | 10 (29.4) | 15 (65.2)        | 0.4 (0.01–13.2)  |          |
| E3/E4    | 2 (5.9)   | 3 (13.0)         | 0.4 (0.01–16.8)  |          |
| p HWE*   | 0.060     | 0.550            |                  |          |
| E3       | 0.61      | 0.78             | 0.004            | 1.0      |
| E2       | 0.32      | 0.13             | 0.08 (0.04–0.18) |          |
| E4 (MAF) | 0.06      | 0.09             | 0.61 (0.2–1.87)  |          |

**FGF** fibrinogen beta polypeptide chain, **HPA-1** human platelet antigen 1, **ACE** angiotensin converting enzyme, **ApoB** Apolipoprotein B-100, **ApoE** apolipoprotein E, *The number of degrees of freedom for the chi-square is equal to 3 for three allele systems and 1 for two allele systems. MAF minor allele frequency. Fisher’s Exact and Chi-square tests were used. Adjusted OR by potential confounders (gender, age, BMI, FH, DM, obesity). Bold values indicate statistically significant at p < 0.05.
significantly associated with dyslipidemia and lipid profile; FVR (4070A > G) with higher total triglyceride ($p = 0.004$) and lower HDL ($p = 0.030$), F13A1 (V35L) and HPA-1 (a/b) with higher LDL ($p = 0.047$ and 0.024, respectively), MTHFR (667C > T) with total cholesterol ($p = 0.004$), and ApoE with triglyceride ($p = 0.002$) and LDL ($p = 0.017$). In addition, similar to DCA plot results, ApoE was also positively correlated with fasting blood sugar levels ($r = 0.267$, $p = 0.044$). However, HPA-1 (a/b) variant showed significant association with patients’ age ($r = -0.352$, $p = 0.007$); youngest age (35.5 ± 10.6) in mutant homozygote individuals, intermediate age (51.3 ± 9.5) in heterozygotes, and later age at onset (56.7 ± 9.0) in normal homozygote carriers ($p = 0.016$).

**Association of traditional risk factors with disease phenotype**

Multivessel disease was more frequent among males ($p = 0.043$) and smokers ($p = 0.020$). Males also had a higher genseni score ($p = 0.048$) with OR (95% CI) of 15 (1.2–18.5). CAD patients who had experienced previous acute coronary ischemic events were two times more likely to have significant occlusion >50% ($p = 0.033$). No association was observed between other traditional risk factors and the degree of CAD at coronary angiography, Table 5. In addition, none of the risk factors showed association with any other clinical characteristics as premature CAD, previous acute coronary ischemic events, echocardiography findings (ejection fraction, diastolic dysfunction, and systolic wall motion abnormalities) in CAD patients (data not shown).

**Association of gene variants with disease phenotype**

As shown in Table 6, CAD patients carrying mutant allele of FVR polymorphism had a lower genseni score ($p = 0.04$) with OR (95% CI) of 0.09 (0.009–0.96) ($r = -0.460$, $p = 0.027$), and lower risk of significant occlusion ≥50% ($p = 0.023$) with OR (95% CI) of 0.08 (0.01–0.64) ($r = -0.536$, $p = 0.008$). In addition, MTHFR 1298A > C mutant homozygotes had a better genseni score ($p = 0.035$).

Association analysis of gene variants with other clinical characteristics and echocardiography parameters showed FVR polymorphism to be inversely related to systolic wall motion abnormalities ($r = -0.416$, $p = 0.048$) and F13A1 (V35L) SNP to be associated with lower ejection fraction in heterozygote compared to normal homozygote ($p = 0.020$) with moderate inverse correlation ($r = -0.50$, $p = 0.015$) (data not shown).

**Discussion**

To our knowledge, this is the first study conducted to investigate the interaction between twelve atherosclerosis and thrombosis related gene variants and the environmental risk factors that could increase the susceptibility to coronary artery disease in Egyptian CAD patients. The previous studies have confirmed that understanding the gene–environment interactions is very important for the development of novel preventive and therapeutic approaches to reduce the risk of CAD [45–47].

In the current study FVR was the most variant associated with CAD patients, combined with the FVL variant to increase CAD risk in one of the patient clusters and with both ACE and MTHFR 667C > T in the second cluster. Because CAD is a multifactorial disorder, its genetic components may be a combined effect of a number of genes with each playing only a small role. Butt et al. [48] have reported that the predisposition imparted by individual genes may act independently or interact with other genes to result in an additive effect or a
synergistic coeffect. The FV:R2 A4070G variant causes amino acid replacement of histidine for arginine at the codon 1299 in the FV B domain. This polymorphism, which marked by the HR2 haplotype was reported to affect the plasma level of FV and contribute to the APC resistance [49]. Although the homo mutant genotype was absent in CAD patients and controls in the current work, this variant confers high susceptibility to CAD risk under the heterozygous and allelic models. Segers et al. [50] suggested that the reduced level of expression of FV:R2 is the most likely explanation for the enhanced thrombophilic phenotype in R2 carriers. Although there are no conclusive data available that associate the R2 haplotype per se with a relevant increased risk of thrombosis (i.e. taken in consideration that FV: Leiden frequency was comparable between CAD patient and control groups in the current study), it was observed previously that male carriers of the FV:R2 polymorphism, have increased circulating levels of FVIII [51]. Although there was no biochemical explanation has been given for this observation, it has been speculated that altered FV anticoagulant activity of FV: R2 results in diminished the proteolytic control of FVIII levels by the protein C pathway [50]. Since increased levels of FVIII are an independent risk factor for the occurrence of venous thrombosis, this may explain the potential association between FV: R2 and thrombosis. Nevertheless, we found that patients carrying the G allele unexpectedly displayed a mild phenotype (i.e. lower Genesi score and lower number of MVD) than wild-type genotype carriers. It seems therefore that the HR2 haplotype in our population preferentially increases the CAD susceptibility but correlates with mild disease severity. It should be kept in mind, however, that thrombosis is a multifactorial disease in which genetic and acquired risk factors interact dynamically. Therefore, the role that FV plays in the etiology of thrombosis is largely dependent on other factors that influence the impact of any altered FV phenotype [50] and the disease outcome depends on

### Table 4

| Haplotypesa | Overall frequency | Controls (n = 34) | Patients (n = 23) | P values | OR (95% CI) |
|------------|-------------------|------------------|------------------|----------|-------------|
| Genotype combination: MTHFR 667C > T/1298A > C |
| CC-AA      | 11 (19.3)         | 8 (23.5)         | 3 (13.0)         | 0.150    | Reference   |
| CT-AA      | 3 (5.3)           | 2 (5.9)          | 1 (4.3)          | 1.3 (0.08–20.7) |
| TT-AA      | 4 (7.0)           | 0 (0.0)          | 4 (17.4)         | 21.8 (0.9–523) |
| CC-AC      | 9 (15.8)          | 6 (17.6)         | 3 (13)           | 1.3 (0.19–9.08) |
| CT-AC      | 14 (24.6)         | 10 (29.4)        | 4 (17.4)         | 1.06 (0.18–6.2) |
| TT-AC      | 1 (1.8)           | 0 (0.0)          | 1 (4.3)          | 7.2 (0.23–225) |
| CC-CC      | 14 (24.6)         | 8 (23.5)         | 6 (26.1)         | 2.0 (0.3–10.9) |
| CT-CC      | 1 (1.8)           | 0 (0.0)          | 1 (4.3)          | 7.2 (0.23–225) |

| Genotype combination: FV 1691G > A/FV 4070A > G |
| GG-AA      | 41 (71.9)         | 28 (82.4)        | 13 (56.5)        | 0.080    | Reference   |
| GG-AG      | 11 (19.3)         | 4 (11.8)         | 7 (30.4)         | 3.7 (0.9–15.18) |
| GA-AA      | 3 (5.3)           | 2 (5.9)          | 1 (4.3)          | 1.07 (0.08–12.9) |
| GA-AG      | 2 (3.5)           | 0 (0.0)          | 2 (8.7)          | 10.5 (0.47–235) |

| Block 1: MTHFR 667C > T/1298A > C |
| CC         | 0.446             | 45.9             | 42.8             | 0.7437   |
| CA         | 0.308             | 36.5             | 22.4             | 0.1114   |
| TA         | 0.218             | 16.5             | 29.8             | 0.0926   |
| TC         | 0.027             | 1.1              | 5                | 0.2134   |

| Block 2: FV 1691G > A/FV 4070A > G |
| GA         | 0.856             | 91.2             | 77.4             | 0.0397   |
| GG         | 0.1               | 5.9              | 16.1             | 0.075    |
| AA         | 0.03              | 2.9              | 3                | 0.9767   |
| AG         | 0.014             | 0                | 3.5              | 0.121    |

MTHFR, Methylenetetrahydrofolate reductase; FV, coagulation factor 5

*aHaploview version 4.1 was used for data analysis. Bold values indicate statistically significant at p < 0.05
the sum of other multiple interacting factors determine the severity of the disease. This finding should be validated in future larger scale studies to be conclusive.

The mutant homozygote TT genotype of MTHFR 676C>T (rs1801133) was found to be more frequent among the studied CAD Egyptian patients (21.7%) and was not found in the controls. This variant showed
significantly higher susceptibility for CAD under homozgyote and allelic models and it was one of the most effective associated gene variants in combination with other variants for clustering our CAD patients by multivariate analysis (i.e. the combined occurrence of the MTHFR 677TT, ACE DD and FVR 4070AG genotypes seems to magnify the CAD risk in our population). MTHFR gene is located on chromosome 1p36.3 and contains more than hundred SNPs, the most studied variants are rs1801133 and rs1801131 that included in the current study. The 667C > T transition in exon 5 of the first SNP is resulting in a change of alanine to valine (A222V) near the FAD (flavin-adenine-dinucleotide) cofactor binding region, and the other variant caused by the point mutation of A to C at nucleotide 1298 of coding sequence leads to substitution of glutamine by alanine at the amino acid number 470 in the protein structure [52]. In silico tools predicted the former variant (i.e. 667C > T) in exon 5 to be deleterious in contrast to the later neutral one. This could explain why MTHFR 667C > T; was associated with CAD risk in our population as the enzyme with valine was shown previously to be associated with increased thermolability and reduced enzymatic activity about 30% if mutant homozygous and 65% if heterozygous [53]. This reduced activity resulting in hyperhomocysteinemia when folate status is low that has been linked to thrombosis and considered as a major independent risk factor for cardiovascular diseases [54]. Similar to our results, when Almawi et al. [55] studied FV Leiden, FV: Leiden or PT 20210 G > A mutations with CAD. The results of the present study are also in agreement with Neto et al. [56] who found the MTHFR 677 T/T genotype to predispose to premature atherosclerotic coronary artery disease, and with Yamada et al. [57] and Schürks et al. [58] who reported increased risk for MI and ischemic stroke, respectively. Otherwise, our findings were in contrast to Hsu et al. [59], Yilmaz et al. [60] and Caner et al. [61] who reported that the MTHFR C677T mutation was not associated with the risk of CAD or venous thrombosis among Chinese in Taiwan nor among Turkish patients, respectively. These contradictory results between different studies could be attributed to relatively small sample size, low frequency of gene variants and ethnic heterogeneity [50].

The plasminogen activator inhibitor-1 (PAI-1) is a 52 kDa glycoprotein encoded by the serine protease inhibitor (SERPINE1) gene [62]. It is secreted by endothelial cells and is stored and released from the platelets during activation to downregulate the fibrinolysis process by inhibiting plasminogen to plasmin conversion induced by either tissue-plasminogen activator or urokinase [63]. The current study functional insertion/deletion promoter variant at -675 position (rs1799989), has been associated with increased risk of atherosclerosis and thrombosis previously with inconsistent results [20, 64–67]. As both the -675 4G and 5G alleles have a binding site for a common transcription activator and the 5G allele has an additional binding site for a repressor, this leads to 5G allele is slightly less transcriptionally active

---

**Table 5** Association between traditional risk factors and clinical characteristics of CAD patients

| Risk factor | Gensini score | P value | Occlusion | P value | No of BVs | P value |
|-------------|--------------|---------|-----------|---------|-----------|---------|
|             | Low | High |         | <50% | ≥50% |         | SVD | MVD |         |
| Number | 14 | 9 | 0.048 | 8 | 15 | 1.00 | 5 (62.5) | 1 (10) | 0.043 |

Gender

|        | Females | Males | Obesity | Smoking | FH CAD | Hypertension | Diabetes | Dyslipidemia | Premature CAD | Previous events |
|--------|---------|-------|---------|---------|--------|--------------|----------|--------------|---------------|----------------|
|        | 6 (42.9) | 8 (57.1) | 2 (14.3) | 6 (42.9) | 2 (14.3) | 7 (50.0) | 4 (28.6) | 11 (79) | 5 (35.7) | 9 (64.3) |
|        | 0 (0.0) | 9 (100) | 3 (33.3) | 7 (77.8) | 4 (44.4) | 3 (33.3) | 3 (33.3) | 8 (88.9) | 4 (44.4) | 9 (100) |
| P value | 0.048 | 0.0162 | 0.343 | 0.197 | 0.162 | 0.669 | 1.00 | 0.100 | 1.00 | 0.0116 |

Smoking 6 (42.9) 7 (77.8) 0.197 4 (50.0) 9 (60.0) 0.685 2 (25) 8 (80) 0.020

FH CAD 2 (14.3) 9 (100) 6 (75.0) 11 (73.3) 3 (37.5) 9 (90) 3 (33.3) 5 (33.3) 1.00

Hypertension 7 (50.0) 3 (33.3) 0.343 0 (0.0) 11 (73.3) 0.122 2 (25) 3 (30) 1.00

Dyslipidemia 11 (79) 8 (88.9) 1.00 6 (75.0) 13 (86.7) 0.589 5 (62.5) 9 (90) 0.275

Premature CAD 5 (35.7) 4 (44.4) 1.00 3 (37.5) 6 (40) 1.00 3 (37.5) 3 (30) 1.00

Previous events 9 (64.3) 9 (100) 0.116 4 (50.0) 14 (93.3) 0.033 7 (87.5) 9 (90) 1.00

Number 14 9 0.048 2 (25.0) 4 (26.7) 1.00 5 (62.5) 1 (10) 0.043

Data are presented as number (percentage). CAD coronary artery disease, FH family history; premature coronary artery disease, <55 years in males and <65 years in females; previous events, previous acute coronary ischemic events, No of BVs number of blood vessels, SVD single vessel disease, MVD multivessel disease. Fisher’s exact test was used. Bold values indicate statistically significant at p < 0.05.
than the 4G and subsequently is associated with lower PAI-1 plasma levels and lower risk of thrombus stabilization [68]. Our results showed no association between PAI-1 4G/5G and the studied sample of CAD patients. This is in line with a previous study on Egyptian population [69] and others [20, 65, 70, 71] that also showed lack of association of this risk variant with MI or CAD. A number of evidences could elucidate our findings; first, the pathogenesis of CAD is complex and multifactorial with multiple interacting environmental and genetic determinants; hence PAI-1 is influenced not only by the gene SNP, but also by environmental factors, such as blood sugar, insulin and triglyceride concentrations among others [66]. Considering this fact, in subgroup stratified analysis, the 4G/4G genotype has been shown to be associated with obesity under the dominant genetic model to be in concordance with Mertens et al. [72], who found increased PAI-1 levels are associated with increased visceral obesity due to its production by ectopic fat depots [73]. In addition, Fernandes and Sandrin [74], found that obese women with 4G/4G genotypes were at increased risk of thrombotic diseases.

Table 6 Association between SNP genotypes and clinical characteristics of CAD patients

| Gene SNP | Gensini score | Occlusion | No of BVs | P value |
|----------|--------------|-----------|-----------|---------|
|          | Low | High | <50% | ≥50% | SVD | MVD | SVD | MVD | P value |
| FVL      |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 11 (78.6) 9 (100) | 0.253 | 7 (87.5) 13 (86.7) | 1.00 | 7 (87.5) 9 (90) | 1.00 |
| H        | 3 (21.4) 0 (0.0) | 1 (12.5) 2 (13.3) | 1 (12.5) 1 (10) |
| FVR      |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 6 (42.9) 8 (88.9) | 0.040 | 2 (25) 12 (80) | 0.023 | 4 (50) 9 (90) | 0.118 |
| H        | 8 (57.1) 1 (11.1) | 6 (75) 3 (20) | 4 (50) 1 (10) |
| F13A1    |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 12 (85.7) 5 (55.6) | 0.162 | 6 (75) 11 (73.3) | 1.00 | 7 (87.5) 6 (60) | 0.314 |
| H        | 2 (14.3) 4 (44.4) | 2 (25) 4 (26.7) | 1 (12.5) 4 (40) |
| MTHFR 1  |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 8 (57.1) 4 (44.4) | 0.558 | 4 (50) 8 (53.3) | 0.962 | 6 (75) 5 (50) | 0.234 |
| H        | 4 (28.6) 2 (22.2) | 2 (25) 4 (26.7) | 2 (25) 2 (20) |
| MTHFR 2  |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 4 (28.6) 4 (44.4) | 0.035 | 4 (50) 4 (26.7) | 0.250 | 2 (25) 4 (40) | 0.167 |
| H        | 3 (21.5) 5 (55.6) | 1 (12.5) 7 (46.7) | 2 (25) 5 (50) |
| M        | 7 (50) 0 (0.0) | 3 (37.5) 4 (26.7) | 4 (50) 1 (10) |
| PAI-1    |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 5 (35.7) 2 (22.2) | 0.730 | 2 (25) 5 (33.3) | 0.660 | 3 (37.5) 3 (30) | 0.869 |
| H        | 6 (42.9) 4 (44.4) | 3 (37.5) 7 (46.7) | 3 (37.5) 5 (50) |
| M        | 3 (21.4) 3 (33.3) | 3 (37.5) 3 (20) | 2 (25) 2 (20) |
| FGB      |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 7 (50) 5 (55.6) | 0.490 | 3 (37.5) 9 (60) | 0.583 | 5 (62.5) 5 (50) | 0.799 |
| H        | 5 (35.7) 4 (44.4) | 4 (50) 5 (33.3) | 2 (25) 4 (40) |
| M        | 2 (14.3) 0 (0.0) | 1 (12.5) 1 (6.7) | 1 (12.5) 1 (10) |
| HPA-1    |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 7 (50) 6 (66.7) | 0.595 | 4 (50) 9 (60) | 0.851 | 6 (75) 6 (60) | 0.610 |
| H        | 6 (42.9) 2 (66.7) | 3 (37.5) 5 (33.3) | 2 (25) 3 (30) |
| M        | 1 (7.1) 1 (22.2) | 1 (12.5) 1 (6.7) | 0 (0.0) 1 (10) |
| ACE      |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| N        | 1 (7.1) 1 (11.1) | 0.829 | 1 (12.5) 1 (6.7) | 0.894 | 0 (0.0) 1 (10) | 0.287 |
| H        | 5 (35.7) 4 (44.4) | 3 (37.5) 6 (40) | 2 (25) 5 (50) |
| N        | 8 4 (44.4) | 4 (50) 8 (53.3) | 6 (75) 4 (40) |
| ApoE     |     |     |   8 | 15 | 8 | 10 |   8 | 10 |         |
| 2/2      | 0 (0.0) 1 (11.1) | 0.492 | 0 (0.0) 1 (6.7) | 0.658 | 0 (0.0) 1 (10) | 0.834 |
| 2/3      | 2 (14.3) 1 (11.1) | 1 (12.5) 2 (13.3) | 1 (12.5) 1 (10) |
| 2/4      | 1 0 (0.0) | 1 (12.5) 0 (0.0) | 0 (0.0) 0 (0.0) |
| 3/3      | 10 5 (55.6) | 5 (62.5) 10 (66.6) | 6 (75) 7 (70) |
| 3/4      | 1 2 (66.7) | 1 (12.5) 2 (13.3) | 1 (12.5) 1 (10) |

Data are presented as number (percentage). CAD coronary artery disease, SNP single nucleotide polymorphism, G genotype, N normal, H heterozygote, M mutant, No of BVs number of blood vessels, SVD single vessel disease, MVD multivessel disease, FV coagulation factor 5, MTHFR 1 and 2 Methylenetetrahydrofolate reductase (rs1801133) and (rs1801131), respectively, PAI-1 plasminogen activator inhibitor-1, FGB fibrinogen beta polypeptide chain, HPA-1 human platelet antigen 1, ACE angiotensin converting enzyme, ApoE apolipoprotein E, Fisher’s exact test was used. Bold values indicate statistically significant at p < 0.05. PTH (Prothrombin) and ApoB (Apolipoprotein B-100) gene variants were excluded from analysis as all patients were normal.
5G/5G genotype in our cases has shown to be protective in patients with positive family history for CAD, to be in line with Margaglione et al. [75]. Second, variability in plasma concentrations of PAI-1 has been reported in different ethnic groups worldwide. The 4G/5G variant has been shown to be the predominant effector in some cases [76–78], while in others environmental factors such as smoking are involved [79].

Human platelet antigens (HPA), platelet surface receptors, play a key role in the adhesion, activation, and aggregation of platelets. They are formed of two glycoprotein (GP) subunits (GPIIb/IIIa) [80]. The GPIIIa subunit is polymorphic [81]. One of the most studied GPIIIa variant, HPA-I a/b (c.176 T > C; Lys59Pro), also known as PIA1/A2, has been suggested as an important genetic key player in the CAD pathogenesis [82]. In the current study, our data demonstrated an association between HPA-1 a/b polymorphism and the occurrence of CAD. We found a significant higher prevalence of HPA-I a/b and HPA b/b genotypes among CAD patients compared to controls. This was consistent with the studies of Weiss et al. [83] and Abboud et al. [84] which reported a strong association between the HPA-1 b allele and genotypes and the risk of CAD. The mutant allele encodes proline instead of lysine at an amino acid position located near the ligand binding site [81]. Bennet et al. [85] showed no impact on ligand binding using static model system. Similarly, our in silico analysis demonstrated L59P mutation to be benign and tolerated. However, in vitro cell culture showed enhanced binding of both fibrinogen and von Willebrand factor (vWF) to the receptor. In the normal population, the HPA-1b phenotype results in increased platelet aggregation and increased fibrinogen binding, thus conferred an increased risk of MI [23, 86], especially in early onset heart disease [83], ischemic stroke [87] and resistance to aspirin [88]. In contrast, other studies reported the absence of any association between the HPA-1a/b missense mutation and the occurrence of coronary diseases [89–92]. This discrepancy could be explained by the finding of Zotz et al. [93] who reported that HPA-1 a/b is a risk determinant in patients with already existing atheromatous burden, but not for the development of atheroma.

One of the most popular genetic risk factors in CAD is the ACE insertion/deletion (rs1799752) polymorphism [94]. The ACE gene is located on chromosome 17q23.3 with 26 exons and 25 introns spreading over about 2 Kb [95]. The presence (insertion) or absence (deletion) of an Alu repetitive element (287-bp repeat sequence) in intron 16 results in I and D alleles, respectively [92]. This common polymorphism accounts for 47% of variations within ACE gene [94]. The results of the current study showed that DD genotype could be a considerable risk factor for CAD susceptibility, particularly in females. There was an increased frequency of D allele in CAD patients (0.72) compared to controls (0.44). No association of the gene was observed with other cardiovascular risk factors highlighting more strong effect of ACE with CAD. In 1992, Cambien and his colleagues reported the earliest significant relationship between the DD homozgyosity and the risk of CAD [96], and that was followed by the study of Morris et al. [97] who suggested that the DD genotype represents a robust risk factor for MI and sudden death compared to II genotype. In addition, DD genotype was associated with coronary artery spasm that is considered one of the mechanisms of MI [98] and increased risk of restenosis with atherosclerotic lesions after percutaneous transluminal angioplasty [99]. Similar findings were further reported in two meta-analysis studies conducted by Samani et al. [100] and Zhou et al. [101]. Furthermore, numerous studies implicated the DD homozgyosity as a key risk factor in other cardiovascular diseases, including hypertension [102], coronary and carotid atherosclerosis [103], cardiomyopathy [104], peripheral arterial disease [105], ischemic stroke [106], and recurrent venous thromboembolism [107]. In contrast, Lindpaintner et al. [108] did not confirm the association between D variant and increased risk of CAD in a large population of American males, and this finding was consistent with that of ours as stratification analysis by gender revealed significant association among females only. ACE, the key regulator in the renin angiotensin system (RAS), has two main physiological functions; converts angiotensin I into a physiologically active peptide angiotensin II (Ang II) and degrades bradykinin, a potent vasodilator [105]. Ang II is the atherogenic component of RAS that increases vascular permeability, stimulates proliferation and migration of vascular smooth muscle cells, induces the expression of inflammatory mediators, and enhances the deposition of extracellular matrix [109]. Reduced bradykinin by ACE decreased endothelium-dependent vasodilators nitric oxide and prostacyclin thus controls blood pressure [103]. The circulatory ACE level is genetically determined by the I/D variant [105]. Individuals with DD genotype have a twofold increase in the serum ACE concentration in the normal population, with ID subjects having intermediate levels [110], leading to higher levels of circulating Ang II and vasoconstriction which are common in MI and hypertensive patients [95]. The results of these studies correlate with those of Suehiro et al. [111] which showed an association between D allele and higher expression of the ACE mRNA that may affect the renin-angiotensin system in local regions. The mechanisms underlying this variation in levels of circulating enzymes by the absence of the Alu repeat sequence within the intron in DD genotype still need to be elucidated.
Two apolipoprotein variants were examined in our study; ApoB-100 R3500Q mutation and ApoE (rs7412 and rs429358). ApoB is the primary apolipoprotein of chylomicrons, VLDL and LDL, which is responsible for carrying fat molecules throughout the body to all tissue cells. The ApoB on the LDL particle acts as a ligand for LDL receptors. High levels of ApoB are the primary drivers of atheroma formation [112]. It is well established that ApoB100 levels are associated with coronary heart disease [113, 114]. Mutations in ApoB gene can cause familial hypercholesterolemia [115]. The R3500Q (rs5742904) mutation in ApoB was found to be a major determinant of LDL levels and coronary artery calcification in the Amish population [112]. Substitution of Arginine with Glutamine is believed to prevent proper folding of ApoB and thereby reducing the ability of LDL particle to bind to the LDL receptor [116]. R3500Q mutation was absent in our study population, possible due to low sample size or ethnic variations. This was consistent with population-based surveys which reported low frequency of R3500Q mutation in non-Amish population [117]. The ApoB gene mutations were not detected in Lebanon [118], Russia [119], Iran [26], and Turkey [120].

The other studied apolipoprotein ApoE is found in chylomicrons and intermediate density lipoprotein (IDL) that is essential for the normal catabolism of triglyceride-rich lipoprotein constituents and cholesterol metabolism [121]. The ApoE gene, mapped on chromosome 19q13.32 in a cluster with ApoC1 and ApoC2, is highly polymorphic [122], with 3 major alleles according to the amino acids at positions 130 (rs429358; c.388 T > C) and 176 (rs7412; c.526C>T) in exon 4: ApoE2 (cys130/cys176), ApoE3 (cys130/arg176), and ApoE4 (arg130/arg176) (ensemble.org). The ApoE polymorphisms were found to affect mRNA transcription and result in increased plasma cholesterol and triglyceride with impaired clearance of lipids from the bloodstream [121]. Moreover, knockout mice lacking ApoE developed extreme hypercholesterolemia after a high-fat diet [123]. In the present study, E3 (rs429358*T, rs7412*C) was the predominant form of gene in both patients and controls followed by E2 variant (rs429358*T, rs7412*C) among the study population, E2 carriers showed protection against developing CAD compared to E3 and E4. Both E3/E3 and E3/E4 genotypes had higher disease risk more than three times when compared to E2 genotypes. ApoE variants were also significantly associated with abnormal triglyceride and LDL-c among our CAD patients. Similar to our findings, E3 isof orm was the most frequent ApoE variant in several populations, including Americans [124], Indians [125], Turkish [126], and Saudians [127], thus is considered the wild type ApoE genotype. The presence of E4 isof orm (rs429358*C, rs7412*C) was previously associated with increased risk of CAD and mortality [128], atherosclerosis [129], and ischemic cerebrovascular disease [130]. Further meta-analyses studies showed ApoE2 allele to be protective while E4 allele rendered higher susceptibility to heart diseases [119, 131–133]. Although these allelic forms differ from each other by only one or two amino acids at 2 sites, these differences alter the ApoE protein structure and function, and thereby have significant physiological consequences [134]. E2 variant with 2 cysteines binds poorly to LDL cell surface receptor compared to E3 and E4, thus can increase the LDLR number, and lowering cholesterol level [122]. On the other hand, E4 isoform with two arginine amino acids exhibits enhanced transfer from HDL to TG-rich lipoproteins, promoting hepatic remnant clearance by ApoE receptors and decreasing LDLR, thereby increasing circulating cholesterol levels [122]. The same variant has also been associated with increased calcium ion levels and apoptosis following mechanical injury [135].

Conclusions
With the caveat that our sample size for this analysis was low, and the current analyses are likely to have been underpowered, our study confirms that CAD development requires more complex interactions among several risk factors [89], including genetic and environmental one. More specifically, it has been found that five variants; rs1800595 (FVR), rs1801133 (MTHFR), rs5918 (HPA-1), rs1799752 (ACE), and rs7412 and rs429358 (ApoE) were significantly associated with CAD susceptibility under different genetic models in the current sample of Egyptian CAD patients. These variants interacted with different traditional risk factors to cluster the current study population into the patient and control subgroups by multivariate analysis application. However, there are some limitations in our study should be considered. First, the study is cross-sectional for the point of the coronary disease investigation and all the study participants were stable CAD patients. Thus, the clinical phenotype was determined up to the time that the study was performed thereby allowing us to detect an association, but not to predict the outcome. Hence, follow-up studies are highly recommended to estimate the effect of the study risk factors on the disease outcome. In addition, including CAD patients with different clinical presentations are recommended to be useful to differentiate the distribution of the genetic pattern analyzed. Second, it is possible that some of our control subjects could have subclinical atherosclerosis that might result in an underestimation of the true risk associated with certain alleles. Additional studies examining coronary angiography free controls, will be of even greater value to more clearly establish the magnitude of risk imparted by the presence of these genetic risk factors. Third, the lack of an association between some variants and CAD may be due to the relatively small sample size that warrant a larger cohort in the same population and in different ethnicity populations to validate the current results.
Additional files

Additional file 1: Table S1. Structural characteristics and functional impact of the studied single nucleotide polymorphisms. Table S2 Odds ratio (95% confidence intervals) for the association between genotypes of thrombogenic gene polymorphisms and CAD risk within strata of cardiovascular risk factors. Table S3 Odds ratio (95% confidence intervals) for the association between genotypes of atherosclerotic gene polymorphisms and CAD risk within strata of cardiovascular risk factors. Table S4 Correlation analysis matrix between genotypes and cardiovascular risk factors. (DOCX 41 kb)

Additional file 2: Figure S1. Genotyping results of the study CAD patients. (DOCX 174 kb)

Abbreviations
ACE: Angiotensin-converting enzyme; APC: Activated protein C; Apo B: Apolipoprotein B; BMI: Body mass index; CAD: Coronary artery disease; CVD: Cardiovascular disease; CaC: Circumflex coronary artery; DCA: Detrended correspondence analysis; FBG: Fasting blood glucose; FGb: Beta-fibrinogen; FV (L): Factor V Leiden; FXIII: Factor 13; HDL: High density lipoprotein; HPA-1: Human platelet antigen 1; LAD: Left anterior descending; LDL: Low density lipoprotein; LMCA: Left main coronary artery; MTHFR; 5,10-Methylenetetrahydrofolate Reductase; MVD: Multivessel disease; PAI-1: Plasminogen activator inhibitor 1; PTH: Prothrombin; RCA: Right coronary artery; SDS: Sodium dodecyl sulfate; TC: Total cholesterol; TG: Triglycerides

Acknowledgements
The authors thank the Oncology Diagnostic Unit and the Center of Excellence, Suez Canal University, Ismailia, Egypt for providing the facilities for performing the research work and thank the patients who agreed to participate in the current study.

Funding
No sources of funding were used for this work.

Availability of data and materials
All data generated or analysed during this study are included in this published article and its Additional files 1 and 2.

Authors’ contributions
MSF, EAT, NMA, AF-E and DIB conceived and designed the experiments, MHH recruited the study samples and clinical patient data, EAT, MSF, NMA, AF-E and DIB contributed parts of the experiments, EAT contributed to the statistical analysis. All authors contributed the reagents and materials needed for the current work, and all authors contributed in writing, reading and approval of the final manuscript.

Competing interest
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was conducted in accordance with the guidelines in the Declaration of Helsinki and it has been approved by the Medical Research Ethics Committee of Faculty of Medicine, Suez Canal University (Approval no. 2734).

Written informed consent was obtained from all participants.

Author details
1 Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 2 Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 3 Clinical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt. 4 Pulmonologist, Ministry of Health, Cairo, Egypt.

Received: 15 October 2016 Accepted: 22 December 2016
Published online: 13 January 2017

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American heart association. Circulation. 2014;129:399–410.
2. Seef S, Jeppson A, Statfjord M. What is killing? People’s knowledge about coronary heart disease, attitude towards prevention and main risk reduction barriers in Ismailia, Egypt (descriptive cross-sectional study). Pan Afr Med J. 2013;15:137.
3. Almahmeed W, Arnaout MS, Chetcuti R, Ibrahim M, Kurdi M, Taher MA, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012;8:65–72.
4. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases.Curr Issues Mol Biol. 2008;10:25–36.
5. Raposo M, Sousa P, Nemeth S, Couto A, Santos M, Pinheiro J, et al. Polypharmacy in cardiovascular diseases (CVD) susceptibility loci in the azores islands (Portugal). Open J Genet. 2011;1:48–53.
6. Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. Hum Genet. 2009;125:467–91.
7. Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011;475:163–5.
8. Himabindu G, Rajasekhar D, Latheef K, Sarma PVGK, Vanajakshamma V, Chaudhury A, et al. Factor V Leiden mutation is not a predisposing factor for acute coronary syndromes. Indian Heart J. 2012;64:570–5.
9. Campo G, Vassari R, Pollina A, Tebaldi M, Ferrari R. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013;132:151–7.
10. Kujovicj JL. Factor V Leiden thrombophilia. Genet Med. 2011;13:1–16.
11. Buzzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L, et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica. 2004;89:1134–8.
12. Ye Z, Liu EH, Higgins JP, Keaveney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and controls. Lancet. 2006;367:651–8.
13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.
14. Kobervivg C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112:225–8.
15. Gemmati D, Serino M, Ongaro A, Tognazzi S, Moraschi S, Resca R, et al. A common mutation in the gene for coagulation factor XIII-A (VAl34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherosclerotic diseases. Am J Hematol. 2001;67:183–8.
16. Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet. 2000;67:985–90.
17. Zetterberg H, Regland B, Palmer M, Ricksten S, Pillqvist L, Rymo L, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012;8:65–72.
18. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-1: Human platelet antigen 1; 3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J. 2007;5:2.
25. Kutlutuk I, Karagöz A, Beşin T, Oduvucu V, Elveran A, Doğan C, et al. Relationship between angiotensin I- converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion. Thromb J. 2014;12:17.

26. Farrokhi E, Shayesteh F, Asadi Mobarakesh S, Roghani Defkordi F, Ghatreh Samani K, Hashemzadeh CM. Molecular characterization of Iranian patients with possible familial hypercholesterolemia. Indian J Clin Biochem. 2011;26:244–8.

27. Zhang M-d G, Gu W, Qiao S-b, Zhu E-j, Zhao Q-rn, LV SZ. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014;9:e95463.

28. Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA. Plasma thrombin-activatable fibrinolysis inhibitor levels and T325I polymorphism as a risk marker of myocardial infarction in Egyptian patients. Acta Cardiol. 2011;66:483–8.

29. Saghafi H, Mahmoodi MJ, Fakhhrizadeh H, Heshmat R, Shafaei A, Larjani B. Cardiovascular risk factors in first-degree relatives of patients with premature coronary artery disease. Acta Cardiol. 2006;61(6):607–13.

30. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

31. Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170:230–9.

32. Janssens ACJ, Lonnidis JP, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Genome Med. 2011;3:16.

33. Schussler JM. Effectiveness and safety of transradial artery access for cardiac catheterization. Proc (Bayl Univ Med Cent). 2011;24:205–9.

34. Saha T, Khalequzzaman M, Akanda A-k, Saha S, Tushar AZ, Ahmed R, et al. Association of GRACE risk score with angiographic severity of coronary artery disease in patients with ST elevation myocardial infarction. Cardiovasc J. 2015;8:30.

35. Scogamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:65–71.

36. Gökdəzən T, Kalaycıoğlu E, Ayanoğlu A, Boyacı F, Turan T, Gür i, et al. Value of coronary artery calcium score to predict severity or complexity of coronary artery disease. Arq Bras Cardiol. 2014;102:120–7.

37. Khandelwal G, Jain A, Rathore M. Prediction of angiographic extent of coronary artery disease on the basis of clinical risk scores in patients of unstable angina. J Clin Diagn Res. 2015;9:OC13–6.

38. Özdemir B, Emül A, Özdemin L, Sağ S, Biçer M, Aydinar A. Association of aortic diameters with coronary artery disease severity and albuminuria. J Low Genit Tract Dis. 2015;19(2):87.

39. Onakol L. Lipids. In: Anderson SC, Cockayne S, editors. Clinical chemistry: an integrated approach. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 166–83.

40. Kotze MJ, Kriegshäuser G, Thiart R, de Villiers NJ, Scholtz CL, Kury F, et al. Simultaneous detection of multiple familial hypercholesterolemia mutations facilitates an improved diagnostic service in South African patients at high risk of cardiovascular disease. Mol Diagn. 2003;7:169–74.

41. Strip assay evaluator Web-edition, Release 2 (version 2.10). http://viennalab.pathology.com. Accessed 14 Oct 2016.

42. Online Encyclopedia for Genetic Epidemiology studies (OEGE). Hardy–Weinberg equilibrium calculator including analysis for ascertainment bias. http://www.oeges.org/software/hardy-weinberg.html. Accessed 14 Oct 2016.

43. Fawzy MS, Hussein MH, Abdelaziz EZ, Yamany HA, Ismail HM, Toraih EA. Relationship between angiotensin I converting enzyme insertion/deletion gene polymorphism and risk for myocardial infarction: evidence of a gene–gene interaction. Blood. 2003;101:3537–41.

44. Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RA. Prevalence of factor V R2 (H299R) polymorphism in the Lebanese population. Pathology. 2006;38:442–4.

45. Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thorax Haemost. 2007;58:530–42.

46. Martinelli I. Risk factors in venous thromboembolism. Thorax Haemost. 2001;8:395–403.

47. Trifonova EA, Spiridonova MG, Stepanov VA. Genetic diversity and the structure of linkage disequilibrium in the methylenetetrahydrofolate reductase locus. Genetika. 2008;44:1410–9.

48. Tajouri L, Martin V, Gasparini C, Ovcaric M, Curtain R, Lea RA, et al. Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catecho1-M-d methylene-thiol transferase (COMT) in multiple sclerosis. Brain Res Bull. 2006;69:327–31.

49. Heidari MM, Khatami M, Hadadzadeh M, Kazemi M, Mahamed S, Malekzadeh P, et al. Polymorphisms in NOS3, MTHFR APOB and TNF-a Genes and Risk of Coronary Atherosclerotic Lesions in Iranian Patients. Res Cardiovasc Med. 2015;6:e29134.

50. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N, Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in angiographically documented coronary artery disease. J Thor Acute Coronary Syndromes. 2004;17:199–205.

51. Neto AI, Moura Jr JP, Persuhn DC. Frequency of MTHFR C677T polymorphism in individuals with early coronary artery disease: cross-sectional study. Sao Paulo Med J. 2013;131:296–300.

52. Yamada Y, Matsuo H, Segawa T, Watanabe S, Kato K, Hibino T, et al. Assessment of genetic risk for myocardial infarction. Thorax Haemost. 2006;66:220–7.

53. Schürks M, Zee RR, Buring JE, Kurtz T. Interrelationships among the MTHFR 677>1 polymorphism, migraine, and cardiovascular disease. Neurology. 2008;71:505–13.

54. Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW, et al. The C677T mutation of the methylene tetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51:141–5.

55. Yilmaz H, Agchan B, Ergen A, Karaalib ZE, Isbir T. Methylenetetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 2004;37:234–8.

56. Caner M, Bircan R, Seviç D, Benif F, Güney A, Kurtoglu N. MTHFR, prothrombin and Factor V gene variants in Turkish patients with coronary artery stenosis. Genet Mol Biol. 2008;31:1836–8.

57. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis, Arterioscler Thromb Vasc Biol. 2001;21:104–17.

58. Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14:DC55–60.

59. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute plasminogen activator inhibitor-1 (PAI-1) and type I levels but not with myocardial infarction or stroke. Am Hear J. 2006;152:1109–17.

60. Li Y, Di C, Liu W, Cai W, Tan X, Xu L, et al. Oncomirs miRNA-221/222 and tumor suppressors miRNA-199a/195 are crucial miRNAs in liver cancer: a systematic analysis. Dig Dis Sci. 2016;61:2315–27.

61. Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 (G145S) polymorphism is associated with coronary artery disease severity: a meta-analysis. Int J Clin Exp Med. 2014;7:3777–88.

62. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 (G145S) gene polymorphism on the thrombotic risk. Thromb Res. 2008;122:826–42.

63. Ismail S, Abdel Azeem AA, Abdel Hamid MA, Nowier SR, Monad H. The role of 4G/5G genetic polymorphism of plasminogen activator inhibitor-1 gene in myocardial infarction among Egyptians. Life Sci. 2011;88:32–9.

64. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen
89. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin
85. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect
71. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack
83. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A
82. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V.
73. Alessi M-C, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1,
72. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF.
71. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack
70. Fawzy et al. BMC Cardiovascular Disorders 2017;17:26
57.118:778–81.
55.32010:2364.
54. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
53. Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene
52. Higaki J, Baba S, Katsuji T, Sato N, Ishikawa K, Mannami T, et al. Deletion
51. Zhou L, Xi B, Wei Y, Shen W, Li Y. Meta-analysis of the association between
50. Fatini C, Gensini F, Sticchi E, Battaglini B, Prisco D, Fedi S, et al. ACE DD
49. Tseng CH, Tseng FH, Chong CK, Tseng CP, Cheng JC. Angiotensin-converting
48. Baselga E, Toole L, Channer K, Woods KL. A meta-analysis of the association of
47. Toole L, Channer K, Woods KL. A meta-analysis of the association between
46. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme
45. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
44. Zeinali N, Hashemi M, Mirmohammadsadeghi M, Mirmohammadsadeghi H,
43. Zotz RB, Winkelmann BR, Muller C, Boehm BQ, Maiz rz W, Scharf RE. Association
42. Di Castelnuovo A, de Gaetano G, Donati MB, Iacovelli L. Platelet glycoprotein
41. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An
40. Sidkandi N, Salzhababea AM. Association of angiotensin-converting enzyme
gene, insertion/deletion polymorphism and saphenous vein graft atherosclerosis in Iranian patients. Braz J Cardiovasc Surg. 2015;30557–61.
39. Demurtas P, Onú G, Coni P, Menetra A, Corrias M, Sirigu P, et al. Association
38. Cambien F, Poiré O, Leefert E, Lvari A, Cambou JP, Averelle D, et al. Deletion
37. Morris BJ. Hypothesis: an angiotensin converting enzyme genotype present in
36. Oike Y, Hata A, Ogata Y, Numata Y, Shido K, Kondo K. Angiotensin
35. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A
34. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
33. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A
32. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V.
31. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein
30. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein
29. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic
28. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PAI 1 and
27. Weiss EJ, Bray PF, Scabini PY, Nicaud V, Bara L, Dawson SJ, et al. The G4S
26. Dawson S, Hamsten A, Wilman B, Henney A, Humphries S. Genetic variation
25. Ye S, Green FR, Scabini PY, Nicaud V, Bara L, Dawson SJ, et al. The G4S
24. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V.
23. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
22. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
21. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
20. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
19. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
18. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
17. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
16. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
15. Floyd CN, Herro A, Warner TD. Expression of the PlA2 allele of glycoprotein
14. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
13. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
12. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
11. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
10. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
9. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
8. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
7. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
6. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
5. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
4. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
3. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
2. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
1. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999;33:1778–83.
71. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack
72. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF.
73. Alessi M-C, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipsise tissue and insulin resistance. Curr Opin Lipidol. 2007;18:240–5.
74. Fernandes KS, Sandrim VC. 4G5G polymorphism modulates PAI-1 circulating levels in obese women. Mol Cell Biochem. 2012;364:299–301.
75. Margaglione M, Cappucci G, Golaizzo D, Guiobini N, Vecchione G, Grandone
76. Dawson S, Hamsten A, Wilman B, Henney A, Humphries S. Genetic variation
77. Ye S, Green FR, Scabini PY, Nicaud V, Bara L, Dawson SJ, et al. The G4S
78. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein
79. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein
80. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein
81. Almawi WY, Mahjoub T. Polymorphisms of human platelet alloantigens HPA-1
82. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V.
83. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A
84. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular
85. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect
86. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin
87. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack
88. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin
89. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin
90. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin
115. Ludwig EH, Hopkins PN, Allen A, Wu LL, Williams RR, Anderson JL, et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res. 1997;38:1361–73.

116. Boeven I, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest. 1998;101:1084–93.

117. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–20.

118. Sabbagh AS, Daher RT, Otrock ZK, Khalek RN, Zaatari GS, Mahfouz RA. ApoB-100 R3500Q mutation in the Lebanese population: prevalence and historical review of the literature. Mol Biol Rep. 2007;34:267–70.

119. Zakerzadeh AM, Djamali A, Nilsen GG, et al. Familial hypercholesterolemia in St Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia. BMC Med Genet. 2005;6:66.

120. Sözen MM, Whittall R, Oner C, Tokatli A, Durukan H, Unlu, et al. The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis. 2005;180:63–71.

121. Wang YL, Sun LM, Zhang L, Xu HT, Dong Z, Wang LQ, et al. Association between apolipoprotein E polymorphism and myocardial infarction risk: a systematic review and meta-analysis. FEBS Open Bio. 2015;5:852–8.

122. Ghebranious N, Ivacic L, Mallum J, Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res. 2005;33:e149.

123. McNeill E, Channon KM, Greaves DR. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci. 2010;118:641–55.

124. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160–5.

125. Ventakaraman P, Reddy C, Ferrell RE. Apolipoprotein E polymorphism in two populations of Andhra Pradesh. Ind J Hum Genet. 1999;5:31–5.

126. Hergenc G, Taga Y, Emek K, Cialikoglu B. Apolipoprotein E genotyping in Turkish myocardial infarction survivors and healthy controls. J Biomed Sci. 1995;2:46–9.

127. Dzimiri N, Meyer BF, Hussain SS, Basco C, Afrane B, Halees Z. Relevance of apolipoprotein E polymorphism for coronary artery disease in the Saudi population. Arch Pathol Lab Med. 1999;123:1241–5.

128. Lenzen HJ, Assmann G, Buchwaldsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778–81.

129. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–30.

130. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology. 1999;53:1308–11.

131. Liu S, Song Y, Hu FB, Niu T, Ma J, Gaziano M, Stampfer MJ. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/4A gene cluster and risk of incident myocardial infarction in men. Atherosclerosis. 2004;177:119–26.

132. Xu H, Li H, Liu J, Zhu D, Wang Z, Chen A, Zhao Q. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014;9:e104688.

133. Zhang Y, Tang HQ, Peng WJ, Zhang BB, Liu M. Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary Heart Disease. Chin Med J (Engl). 2015;128:1391–8.

134. Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.

135. Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury. Neuroscience. 2015;301:375–83.